New combo pill for fluid retention passes first Body-Processing test in healthy volunteers
NCT ID NCT07046975
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial enrolled 24 healthy adults to see how a new fixed-dose combination tablet containing extended-release torsemide and spironolactone is absorbed and eliminated. Participants took either the combo pill or separate tablets of each drug. Researchers measured drug levels in blood and urine to compare how the body handles the two forms. The study does not test treatment for any disease, only how the drugs behave in healthy people.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Torsemide and Spironolactone (fixed-dose combination tablet)
What this could lead to
If successful, this could lead to a simpler, once-daily pill for conditions like heart failure or high blood pressure that require both drugs.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. It only checks how the body handles the drug, not whether it works for any disease. The combination may not prove better than taking the drugs separately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOAVAILABILITY HEATHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sarfez Pharmaceuticals
Vienna, Virginia, 22182, United States